Impact of Rapid Detection of MRSA

Withdrawn before enrolling

Conditions studied: Staphylococcus Aureus Infections

In brief

The objective of this study is to evaluate the impact of the Alere\™ PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized patients with sterile site S. aureus infection.

Key facts

Study ID

NCT02027389

Run by

Mayo Clinic

People needed

0

Starts

2014-01-01

Expected to finish

2016-07-01

Last updated by the study team

2018-02-13

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Inpatients (adults and children) at Mayo Clinic, Rochester with sterile source S. aureus cultures (both control and intervention periods)
• Above, with rapid PBP2a testing (intervention period only).

You may not qualify if…

• Patients with polymicrobial cultures (i.e., growth of S. aureus plus other organisms in the culture).
• Patients who have not provided MN authorization to use their medical records for research.
• Patients who have had the FilmArray Blood culture identification diagnostic test performed on an index S. aureus blood culture.
• Patients who have had a sterile source S. aureus culture within the prior 30 days.

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.